ClinicalTrials.gg
CompletedNCT04273282Updated Dec 11, 2020

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

A Phase 4 interventional study of Dexycu intracameral dexamethasone and Prednisolone Acetate in Cataract, sponsored by Research Insight LLC. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.

Enrollment
11th of 12
31 · median 62
Started
2019
the only one that year
Phase 4
9 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Research Insight LLC

Among the 12 studies testing moxifloxacin in Cataract, this one is the 11th largest by enrollment, is the only one that started in 2019, is one of 9 in phase 4, and was the 10th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About moxifloxacin

Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing moxifloxacin in Cataract, or all of them as a file.
02

Study summary

This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract surgery.

Read the detailed description

On initial consultation, each study subject will be randomized by a table in the possession of investigators to receive one of two treatment groups, either experimental or control in the first eye. The second eye will undergo cataract surgery approximately 2 weeks later and will be treated with the other treatment group:

Dexycu Group: A total of 30 study subjects will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa each day after surgery for 4 weeks.

Control Group: A total of 30 study subjects will receive topical moxifloxacin 0.5% four times per day 1 day prior to surgery and for ten days postoperatively, Prolensa every day 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% four times per day starting at the conclusion of cataract surgery for 2 weeks and twice per day for 2 weeks in their scheduled surgical eye.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female in good general health, greater than 18 years of age at time of screening.
  • Must be able to comprehend and willing to give .
  • Woman of must not be pregnant or lactating.
  • Subject has availability, willingness, and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits.
  • Subject with cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned.
  • Subject with an OCT of the macula in both eyes that demonstrates no significant pathology.

Exclusion criteria

Exclusion Criteria:

  • Subject with any signs of intraocular inflammation in either eye at screening.
  • Subject with a known sensitivity to any of the study medications.
  • Subject with only one eye with potentially good vision.
  • Subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening.
  • Subject with pupil abnormalities.
  • Subject with corneal abnormalities.
  • Subject with a history of chronic/recurrent inflammatory eye disease in either eye.
  • Subject with uncontrolled glaucoma.
  • Subject expected to undergo surgical intervention and/or ocular laser treatment prior to or during the study period.
  • Subject who requires use of systemic or ocular medications that may affect vision, ocular inflammation, or pain.
  • Subject with an acute or chronic disease or illness that would increase risk or confound study results, e.g. disease, etc.
  • Subject with an uncontrolled systemic disease.
  • Subject with poorly-controlled diabetes.
  • Subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
31 participants (actual)

Study arms

  • Active comparator
    Dexycu Group

    A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.

    Drug: Dexycu intracameral dexamethasone

  • Active comparator
    Control Group

    A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.

    Drug: Prednisolone Acetate

Interventions

  • To evaluate the safety and ocular efficacy of Dexycu.

    Also known as: Moxifloxacin 0.5%, Prolensa

  • To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.

06

What researchers measure

Primary outcomes

  1. Patient preference for medication protocol in 30 randomized subjects

    Patient preference for medication protocol between the two eyes, as reported based on the question, "Thinking about your overall experience taking medications in each eye after surgery, which eye did you prefer? Questionnaire

    Time frame: Day 28

Secondary outcomes

  1. Subject evaluation of postop ocular pain in 30 randomized subjects

    Study subject evaluation of post-op ocular pain.

    Time frame: Day 28

  2. Summed Ocular Inflammation Score in 30 randomized subjects

    Summed Ocular Inflammation Score (sum of the mean anterior chamber cells and anterior flare score)

    Time frame: Day 28

  3. Medication cost in 30 randomized subjects

    Cost of medications to the patient (patient-reported)

    Time frame: Day 28

07

Study locations

2 sites
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
  • Ophthalmic Consultants of Long Island
    Garden City, New York 11530, United States
08

References and documents

Publications

  • Hovanesian JA, Donnenfeld ED. Intracameral dexamethasone 9% vs prednisolone acetate 1% in controlling postoperative pain and inflammation in patients undergoing cataract surgery. J Cataract Refract Surg. 2022 Aug 1;48(8):906-911. doi: 10.1097/j.jcrs.0000000000000887. Epub 2022 Jan 18. PubMed 35067660 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2020, 11 months.

Of 46 phase 4 interventional studies under Cataract, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Feb 18, 2020
StartActual
Dec 16, 2019
Primary completionActual
Nov 24, 2020
CompletionActual
Nov 24, 2020
Last update
Dec 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04273282
Lead sponsor
Research Insight LLC
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Dec 16, 2019
Primary completion
Nov 24, 2020
Completion
Nov 24, 2020
Last update
Dec 11, 2020

Study contacts

John Hovanesian, MD
principal investigator · Research Insight LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion